Pharmacy News

  • Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy
    NEW YORK–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, today announced that it will host a meeting on Wednesday, June 20, 2012 to review its late-stage product development pipeline and commercialization strategy. The meeting will feature therapeutic area presentations by senior leadership from the Forest Research Institute, Inc., the Company’s research and development arm, and product commercialization strategy by
  • Cubist Announces Positive Results from ENTEREG® Phase 4 Study in Patients Undergoing Radical Cystectomy
    LEXINGTON, Mass.–(BUSINESS WIRE)–Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that a Phase 4 study of ENTEREG® (alvimopan) in patients undergoing radical cystectomy met its primary endpoint of time to achieve recovery of both upper and lower gastrointestinal (GI) function. All secondary endpoints, including length of hospital stay, also achieved statistical significance. Delayed recovery of GI function is one of the most common complications prolonging hospital stay in patients
  • Affymetrix to Host Conference Call on May 3, 2012 to Announce First Quarter 2012 Operating Results
    SANTA CLARA, Calif.–(BUSINESS WIRE)–Affymetrix, Inc. (NASDAQ: AFFX) today announced that its first quarter 2012 operating results will be reported after market close on Thursday May 3, 2012. The company will also hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the investor relations section of the company’s website at Alternatively, investors and other interested parties may listen to the live conference call by dialing 877-40
  • BioAlliance Pharma: Full-Year Financial Results for 2011
    PARIS–(BUSINESS WIRE)–annual results
  • Research and Markets: What Do Patients Think of Pharma’s HIV/AIDS R&D? Study Features 20 Pharma Companies and 32 Biotech Companies
    DUBLIN–(BUSINESS WIRE)–Research and Markets ( has announced the addition of the “What Do Patients Think of Pharma’s HIV/AIDS R&D?” report to their offering. In 2011, two important events occurred in the world of research into HIV/AIDS treatment. Firstly, as a response to the continued rise in the global numbers of people living with HIV/AIDS, the United Nations issued a June 2011 political declaration aimed at intensify
  • Research and Markets: Brazil Retail Report Q2 2012 – Over-The-Counter (OTC) Pharmaceutical Sales to Increase from an Expected US$5.53bn in 2012 to US$8.85bn By 2016
    DUBLIN–(BUSINESS WIRE)–Dublin – Research and Markets ( has announced the addition of the “Brazil Retail Report Q2 2012” report to their offering. The Q212 BMI Brazil retail report forecasts that the country’s retail sales will grow by nearly 43% between 2012 and 2016, from BRL1.59trn (US$866.36bn) to BRL2.27trn (US$1.24trn). Retail sub-sectors that are expected to show strong growth over the forecast period include food and
  • Bard to Host Earnings Conference Call on April 24, 2012
    MURRAY HILL, N.J.–(BUSINESS WIRE)–C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Tuesday, April 24, 2012 at 5:00 PM EDT, to discuss the company’s first quarter 2012 operating results, and to provide financial guidance for the second quarter of 2012. Bard is scheduled to issue an earnings press release after the market closes on April 24, 2012. A live audio webcast of Bard’s investor conference will be accessible to all investors through Bard’s website at ht
  • New Image-Pro Premier Image Analysis Software Accelerates Life Science & Industry
    BETHESDA, Md.–(BUSINESS WIRE)–Image-Pro Premier image analysis software offers intuitive tools that make it easy to capture, process, measure, analyze and share your images and valuable data.
  • Q-Med Discontinues the Breast Indication for Macrolane
    UPPSALA, Sweden–(BUSINESS WIRE)–Macrolane is a safe and well-tolerated injectable product used to augment body contour and correct soft tissue defects. Introduced in 2008, it has improved the quality of life of thousands of patients in indications ranging from HIV-related lipoatrophy to breast augmentation. A safety reporting system has been in place since launch and no safety concerns have been identified. However, all breast augmentation procedures, including those involving Macrolane, can i

Digest powered by RSS Digest


Leave a Reply